NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Jupiter Neurosciences, Inc. (JUNS) Stock Analysis

Jupiter Neurosciences, Inc. (JUNS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

JUNS

$3.28

+$0.02 (+0.61%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare JUNS with… →

JUNS Key Statistics

As of Sep 4, 2026
Trading
Open
$3.36
Previous Close
$3.26
Day's Range
3.27–3.61
52-Week Range
2.88–138.00
Volume
25.00K
Valuation
Market Cap
$4.32M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
54.67
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
66.85
EPS (ttm)Profit attributable to each share over the last twelve months.
−18.70
Financials (FY)
Revenue (FY)
$21.80K
Net Income (FY)
−$8.64M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.32M
1-Year Return
+162.40%
Dividend and dates
Avg Volume
997.58K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

JUNS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+221.57%
2025−90.47%
2024 (partial year)+94.90%

As of September 4, 2026.

JUNS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$21.80K−$8.64M−39662.8%
2024$0.00−$2.44M—
2023$0.00−$4.78M—
2022$233.28K−$4.96M−2125.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$21.80K$17.57K−$8.91M−$8.64M−39662.8%
2024$0.00—−$3.09M−$2.44M—
2023$0.00—−$3.87M−$4.78M—
2022$233.28K—−$3.43M−$4.96M−2125.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

JUNS Valuation vs Biotechnology Median

Median of 656 stocks
MetricJUNSBiotechnology medianvs median
P/S ratio66.8515.264.4x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Jupiter Neurosciences, Inc. (JUNS) at $4.32M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 5 employees.

JUNS last closed at $3.28 on September 4, 2026. That is +$0.02 (+0.61%) against the previous close. The 52-week range on file runs from $2.88 to $138.00. The latest close sits 13.89% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $21.80K. The same year closed with a net loss of $8.64M. The reported profit margin is 0%. Trailing earnings per share are −18.7.

Across the 4 fiscal years on file, revenue moves from $233.28K in 2022 to $21.80K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 54.67. The price-to-sales ratio is 66.85. On price-to-sales that is 4.4 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Daily returns over the trailing 1 year annualize to a volatility of 6,693.01%. The trailing one-year price return is +162.40%. The stored price history starts on December 3, 2024, and the total return since then is −40.26%.

Growth & Income

No dividend is on file for JUNS.

The record holds one complete calendar year, 2025, which returned −90.47%. So far in 2026 the price is +221.57%.

Peer Comparison

Jupiter Neurosciences, Inc. (JUNS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Jupiter Neurosciences, Inc. JUNS $4.32M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Jupiter Neurosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

Visit website →